Try

Intra-Cellular Therapies, Inc.

ITCIUnited States

39 filed reports · 320 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$681MFY2024 · to Dec 31, 2024+46.6% from $464M10-K$199MQ4 FY2024 · to Dec 31, 2024+50.8% from $132M10-K
Net income-$74.7MFY2024 · to Dec 31, 2024a year earlier: -$140M10-K-$16.9MQ4 FY2024 · to Dec 31, 2024a year earlier: -$28.6M10-K
Operating income-$117MFY2024 · to Dec 31, 2024a year earlier: -$159M10-K-$38.8MQ3 FY2024 · to Sep 30, 2024a year earlier: -$29.7M10-Q

Filed reports

39 reports · Jun 2015 to Dec 2024

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR292,797Jun 2015 to Sep 2024
Annual · 10-KSEC EDGAR103,140Dec 2015 to Dec 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY202410-KDec 31, 2024Feb 21, 2025756Open
FY2024 Q310-QSep 30, 2024Oct 30, 2024178Open
FY2024 Q210-QJun 30, 2024Aug 7, 2024142Open
FY2024 Q110-QMar 31, 2024May 7, 2024144Open
FY202310-KDec 31, 2023Feb 22, 2024321Open
FY2023 Q310-QSep 30, 2023Nov 2, 2023114Open
FY2023 Q210-QJun 30, 2023Aug 3, 202399Open
FY2023 Q110-QMar 31, 2023May 4, 2023103Open
FY202210-KDec 31, 2022Mar 1, 2023288Open
FY2022 Q310-QSep 30, 2022Nov 3, 202290Open
FY2022 Q210-QJun 30, 2022Aug 9, 202286Open
FY2022 Q110-QMar 31, 2022May 10, 202295Open

Financial data

320 concepts · 5,937 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial311 concepts · 5,852 facts · Dec 2013 to Dec 2024

  • Cash and cash equivalents at carrying value56 · Dec 2013 to Dec 2024
  • Comprehensive income net of tax56 · Dec 2013 to Dec 2024
  • Investment income interest56 · Dec 2013 to Dec 2024
  • Net income loss56 · Dec 2013 to Dec 2024
  • Operating income loss56 · Dec 2013 to Dec 2024
  • Research and development expense56 · Dec 2013 to Dec 2024
  • Share based compensation56 · Dec 2013 to Dec 2024
  • Depreciation54 · Dec 2013 to Dec 2024
  • General and administrative expense (US GAAP)54 · Dec 2013 to Sep 2024
  • Increase decrease in accounts payable54 · Dec 2013 to Dec 2024
  • Increase decrease in prepaid deferred expense and other assets54 · Dec 2013 to Dec 2024
  • Proceeds from sale maturity and collections of investments54 · Dec 2013 to Dec 2024
  • Proceeds from stock options exercised54 · Dec 2013 to Dec 2024
  • Accretion amortization of discounts and premiums investments53 · Sep 2014 to Dec 2024
  • Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent53 · Sep 2014 to Dec 2024
  • Payments to acquire investments53 · Sep 2014 to Dec 2024
  • Stockholders equity (US GAAP)53 · Dec 2013 to Dec 2024
  • Common stock shares issued52 · Dec 2014 to Dec 2024
  • Issuance of stock and warrants for services or claims52 · Dec 2014 to Dec 2024
  • Payments to acquire property plant and equipment52 · Dec 2013 to Dec 2024
  • Accounts payable current51 · Dec 2014 to Dec 2024
  • Accrued employee benefits current51 · Dec 2014 to Dec 2024
  • Accrued liabilities and other liabilities51 · Dec 2014 to Dec 2024
  • Accumulated other comprehensive income loss net of tax51 · Dec 2014 to Dec 2024

Product2 concepts · 67 facts · Dec 2018 to Dec 2024

  • Revenue52 · Dec 2019 to Dec 2024
  • Advertising expense15 · Dec 2018 to Dec 2024

Segment7 concepts · 18 facts · Dec 2023 to Dec 2024

  • Revenue6 · Dec 2023 to Dec 2024
  • Cost Of Product Sales2 · Dec 2023 to Dec 2024
  • Net income loss2 · Dec 2023 to Dec 2024
  • Research and Development Expense, Other2 · Dec 2023 to Dec 2024
  • Segment reporting other item amount2 · Dec 2023 to Dec 2024
  • Selling, General and Administrative Expense, General and Administrative2 · Dec 2023 to Dec 2024
  • Selling, General and Administrative Expense, Selling2 · Dec 2023 to Dec 2024

Segments

85 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service3 members · 67 facts

  • Collaborative Arrangement, Product [Member]26 · Dec 2019 to Dec 2024
  • Grant revenue [Member]26 · Dec 2019 to Dec 2024
  • CAPLYTA [Member]15 · Dec 2018 to Dec 2024

Statement business segments1 member · 18 facts

  • Reportable Segment18 · Dec 2023 to Dec 2024

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Intra-Cellular Therapies, Inc. (ITCI) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.